Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914059 | 0.92 | GRM5 (0.40) | GRM5RAB9AL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL2920741 | 0.79 | GRM5 (0.38) | GRM5LMNARAB9AKMT2AALDH1A1 | |
| SCHEMBL2921956 | 0.72 | GRM5 (0.47) | MAPK14GRM5HSD17B13LMNAMAPT | |
| SCHEMBL2919979 | 0.68 | GRM5 (0.47) | MAPK14GRM5HSD17B13LMNAALDH1A1 | |
| SCHEMBL2890722 | 0.67 | HCRTR1 (0.38) | GRM5 | |
| SCHEMBL2890728 | 0.67 | HCRTR1 (0.38) | GRM5 | |
| SCHEMBL2916685 | 0.67 | GRM5 (0.57) | MAPK14GRM5HSD17B13LMNAMAPT | |
| SCHEMBL2913730 | 0.65 | GRM5 (0.57) | GRM5RAB9AALDH1A1MAPK1 | |
| SCHEMBL17922502 | 0.65 | NOTUM (0.47) | RAB9AL3MBTL1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1544945 | 0.64 | KCNH2 (0.45) | GRM5LMNARAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212316-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | claimed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054794-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111821-A1 | AMINO 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | MAPK14 1289/4885GRM5 1/4885HSD17B13 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.